<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The vision</td>
<td>5</td>
</tr>
<tr>
<td>Birmingham Health Partners</td>
<td>7</td>
</tr>
<tr>
<td>Inside the ITM</td>
<td>9</td>
</tr>
<tr>
<td>Why Birmingham?</td>
<td>12</td>
</tr>
<tr>
<td>Success stories</td>
<td>15</td>
</tr>
<tr>
<td>Centres of excellence</td>
<td>16</td>
</tr>
<tr>
<td>Our people</td>
<td>18</td>
</tr>
<tr>
<td>Our history and our future</td>
<td>21</td>
</tr>
<tr>
<td>Business engagement</td>
<td>23</td>
</tr>
<tr>
<td>ITM floor plans</td>
<td>24</td>
</tr>
</tbody>
</table>
The vision

In 2015 there will be a unique opportunity to launch a world-class service – based in Birmingham – that will connect patients with clinicians and trials teams embedded in personalised medicine.

The Institute of Translational Medicine (ITM) will host the facilities and expertise to make this happen: using pioneering science to accelerate the delivery of stratified healthcare.

The aim is to cure disease and save lives by applying transformative science and technology and by educating and training the healthcare workforce.

The ITM will speed up the rate at which research can improve patient treatments and outcomes by using a multi-disciplinary, highly-collaborative approach that will include all components of the bench-to-bedside pathway. It will facilitate the rapid and cost-effective assessment of new drugs, medical devices and diagnostics to quickly bring them to market and frontline clinical use.

Who benefits?
Personalised medicine (or stratified medicine) is recognised as a key global priority for healthcare providers, pharmaceutical and diagnostic industries and patients.

The approach subdivides patients into groups based on their risk of developing specific diseases or their response to particular therapies.

In the past decade there has been a revolution in the opportunities for, and approach to, biomedical research. Recent insights into the basic biology of human disease have generated a wave of new diagnostics, drugs and devices.

For patients to benefit from these advances as quickly as possible it is essential that they are tested – and there is no better place than Birmingham to do this.

Birmingham has the youngest age profile of any city in the UK. Its large catchment region encompasses population scale and diversity, giving access to one of the largest patient cohorts in Europe.

The region is unique in its combination of this population size (5 million-plus), high ethnic and socio-economic diversity, diversity of clinical specialty delivery, a highly stable and large proportion of young people and accessibility to patients through established networks of primary, secondary and tertiary providers. Access to such a population base is crucial to advanced and comprehensive translational research and impossible without it.

Patients will receive access to a range of new, more effective, targeted treatments.

Scientists will be able to develop new drug treatments that target specific genetic faults and design more efficient clinical trials.

Clinicians will be given access to high-quality genetic tests that enable them to tailor treatment for each patient.

The NHS will benefit from time and cost savings.
The ITM is being delivered by Birmingham Health Partners (BHP), a collaboration which brings together the clinical, scientific and academic excellence of University Hospitals Birmingham NHS Foundation Trust (UHB), the University of Birmingham (UoB) and Birmingham Children’s Hospital NHS Foundation Trust (BCH).

The ITM will be at the heart of an internationally-recognised, clinical academic community, whose competitive advantages are unrivalled in the UK and include:
- **State-of-the-art clinical facilities.**
- **Patient population – scale and diversity.**
- **Established IT infrastructure.**
- **Renowned clinical trials expertise.**

**Successful commercialisation of healthcare innovation.**

Together, UHB, UoB and BCH will capitalise on the city’s leading position in Life Sciences and its unique assets as a location for clinical trials.

This scale and co-location of resource is likely to be increasingly important in a rapidly evolving global healthcare economy.

---

**KEY**

A. Queen Elizabeth Hospital Birmingham (QEHB)
B. NIHR Surgical Reconstruction and Microbiology Research Centre
C. Centre for Translational Inflammation Research
D. NIHR Trauma Management HTC
E. Institute of Biomedical Research
F. University of Birmingham Medical School
G. NIHR/Wellcome Trust Birmingham CRF
H. Advanced Therapy Facility
I. Institute of Translational Medicine
J. NHSBT Cell Immunotherapy Lab
K. CRUK Clinical Trials Unit
L. Biomedical Innovation Hub
M. School of Sport, Exercise and Rehabilitation Sciences
N. School of Health and Population Sciences
O. College of Life and Environmental Sciences
P. University of Birmingham
Q. Centre for Clinical Haematology

---

**BHP profile**

![Image](image-url)

- 27 innovations taken from concept to commercialisation in the past five years
- 30 biomedical innovations licensed to the healthcare industry in the past five years
- 500 patents
- 20 active spin-off firms

**Transferring knowledge**

by actively engaging with industry

**Active licensing**

of a large portfolio of medical, biomedical, engineering and environmental patents
Inside the ITM

The alliance between UHB, UoB and BCH, under the auspices of BHP, has fostered an environment that attracts nationally and internationally renowned clinicians and investigators at the forefront of their fields.

This partnership serves to make Birmingham – with the ITM at its heart – one of few centres internationally that can complete the full circle of translational medicine.

The ITM will offer a single point of entry for individuals, organisations and businesses seeking to maximise biomedical research translation for the benefit of industry, the economy and, ultimately, patients.

Research networks
As a central meeting point and working hub, it will allow clinicians, academics, methodologists, patient groups and industry partners to maximise their interaction and develop productive collaborative networks.

It will facilitate the efficient assessment of cost-effective new drugs, medical devices and diagnostics to more rapidly bring them to market and use within mainstream clinical settings.

It will include a large clinical area that will provide an infrastructure for the recruitment and follow-up of patients participating in the translational research programmes within the ITM.

Programmes of clinical trials will evaluate the effects and safety of new therapies in NHS practice, taking findings from first-in-man studies to definitive studies evaluating the impact on patient-important outcomes, such as survival and quality of life. Trials will evaluate a tailored ‘personalised’ approach to healthcare.

Access to industry
The ITM will build a vibrant translational community to facilitate the collaborative relationships with industry that are required for fast and efficient evaluation of new treatments and healthcare innovations in NHS practice.

It will work closely with the West Midlands Academic Health Science Network which brings together inward investment, expertise, knowledge and energy from across the entire community.

The ITM will engage widely with industry, bringing together all professional groups that are involved in the design and delivery of clinical and translational research, breaking down traditional divisions to deliver a truly integrated, patient-centred approach.

Infrastructure

The ITM hosts five key thematic areas involving internationally-renowned clinical and non-clinical academics conducting integrated research programmes:

1. Cancer
2. Devices and Diagnostics
3. Rare Diseases
4. Auto-immune Disease
5. Chronic Disease (non-Cancer)

These five thematic areas are supported by five core infrastructure components:

1. Commercial hub
2. Early phase clinical trials unit (first-in-human to phase II)
3. Stratified Medicine (genomics; deep immunophenotyping; metabolomics)
4. Informatics (clinical informatics and bio-informatics)
5. Health and Population Sciences (health economics; biostatistics; patient-reported outcomes).
The number of medical technology companies in the West Midlands – the largest concentration in the UK

66%
Of all UK life science companies are in the medical technology sector

44%
Of the total number of companies in the medical technology sector are located in the West and East Midlands

£17.6bn
Turnover for the UK medical technology sector

£5bn
R&D funding for the UK pharmaceutical sector

6–8%
Annual employment growth between 2009–2013 in the medical technology sector

£230m
Live research funding for the College of Medical & Dental Sciences

160
Active trials currently in progress through the Birmingham Centre for Clinical Trials

90%
The amount of research carried out by the University of Birmingham that has global reach (source: UK Research Assessment Exercise)

£12.8m
The largest NIHR CRF award nationally for the NIHR/Wellcome Trust Birmingham Clinical Research Facility

15
The number of universities within an hour’s drive from Birmingham city core

12th
The University of Birmingham’s ranking in the UK overall (out of 159 institutions) in the Research Fortnight University Power Ranking, based on the quality and quantity of UK universities’ research output

200
The number of active clinical trials being run by UHB at any one time

4,980
The number of companies in the UK developing, producing and marketing products and services in the pharmaceutical, medical technology, medical biotechnology and industrial biotechnology markets

573
The number of medical technology companies in the West Midlands – the largest concentration in the UK

10,778
The number of UHB patients successfully recruited to participate in research (2013/14)
Inside the ITM

The ITM locates, in a single facility:

Education and training facilities

... which will provide the infrastructure and expertise to deliver a diverse and compelling educational programme in translational medicine. This will include a portfolio that ranges from short-targeted training modules in specific aspects of stratified medicine, through to post-graduate diplomas and degrees based in the ITM and leading to a UoB qualification.

Commercial hub

... acting as a single access point focused on delivering the requirements of industry by rapidly identifying and coordinating the specific expertise required for the partner.

The hub will include office space and networking facilities, bringing together clinicians, researchers and industry in an atmosphere of innovation and collaboration.

Leading experts in health economics and patient reported outcomes will facilitate the early application of robust assessment and analysis to inform decisions on new treatments and devices and to assess their impact on whole populations.

Health and population sciences

... with the ITM giving access to internationally-recognised experts at UoB, who will provide the innovative, multidisciplinary expertise in study design required for full translational medicine capability. This expertise will include trials methodology, stratified medicine, diagnostics, evidence synthesis and health economics.

It will incorporate a base for UoB’s outstanding patient-reported outcomes group and world-class expertise in biostatistics, particularly related to test evaluation and risk stratification.

Stratified medicine hub

... linked to research facilities for genotyping and deep immunophenotyping (mass cytometry, metabolomics).

The West Midlands will also deliver one of 11 centres across England that will lead the way in delivering the 100,000 Genomes Project while the hub gives access to the West Midlands regional Genetics Laboratory based at Birmingham Women’s Hospital, which provides a comprehensive genetics testing service to NHS patients within the region.

Key clinical academic groups

... conducting internationally-recognised research, including programmes in cancer, autoimmune diseases, chronic diseases, acute diseases and trauma, transplantation, rare diseases, paediatric and paediatric/adult transition medicine.

It will bring together leading academics in one location, will build critical mass, increase capacity and develop synergies in clinical research.

Clinical trials facilities and personnel

... with a focus on early phase trials and capacity for trial design, novel methodology, delivery and analysis across key disease areas and all types of healthcare innovation.

Informatics hub

... which will integrate complex clinical and demographic data sets generated by UHB and BCH with biological data generated by research groups located in the ITM and elsewhere in UoB, to allow advanced data mining and analysis.

This will provide a unique opportunity to explain mechanisms of disease from the cellular level through to the whole patient, to identify discriminative features (eg, biomarkers and endotypes) and to stratify patients.
Birmingham

Birmingham has an international airport and will be served by the planned first phase of the High Speed 2 (HS2) rail link to London. In July 2014 Birmingham was announced as the location of the HS2 construction headquarters, which will create 1,500 jobs during the construction phase, which is due to begin in 2017. Already, the first phase of redevelopment at the former Battery Park site in Selly Oak, close to the UoB/UHB campus, is underway. This major investment will bring a range of benefits through:

- A cutting-edge Life Sciences Campus.
- Creation of 2,700 jobs.
- A range of shops, bars and restaurants, plus good parking.
- A new Sainsbury’s store.
- Environmental improvements with major site decontamination and extensive landscaping.
- Excellent pedestrian and cycle links.
- A greenway across the site that will protect the future reinstatement of a canal link.
- Highways improvements being in place before the development is completed.

University Hospitals Birmingham (UHB)

The £545m Queen Elizabeth Hospital Birmingham (QEHB), run by UHB, was opened in 2010 and hosts a range of leading-edge local, regional and national services, including the largest solid organ transplantation programme in Europe; the largest renal transplant programme in the UK; a specialist centre for liver, heart and lung transplants and cancer studies; and the Royal Centre for Defence Medicine.

UHB houses state-of-the-art clinical informatics, with one of the most advanced electronic data systems in the world.

Clinical, prescribing and outcome data are all captured on an integrated database permitting advanced analysis of patient outcomes and rapid identification of suitable patients for clinical trials.
The University of Birmingham (UoB)

UoB brings people from across the world to the city, including researchers and teachers and more than 4,000 international students from nearly 150 countries.

Home to nearly 30,000 students and more than 7,500 postgraduate students, UoB plays an integral role in the economic, social and cultural growth of local and regional communities; working closely with businesses, employing 6,000 staff and providing 10,000 graduates annually.

UoB is in the midst of one of the most exciting and transformational campus redevelopments since the first phase of building on the Edgbaston campus was completed in 1909 under the auspices of Sir Aston Webb. The development projects, worth close to £400 million over the next five years, will create outstanding new facilities which will benefit students, staff, visitors and the local community – whilst drawing on Aston Webb’s original campus masterplan, as well as subsequent plans, and laying a sound basis for the future.

Birmingham Children’s Hospital (BCH)

BCH is the largest specialist UK centre for paediatric diabetes, childhood cancer, intestinal transplantation and inherited metabolic diseases and has recently been selected as one of only three UK National Specialist Commissioning Advisory Group (NSCAG) Lysosomal Storage Disease treatment centres.

BCH, together with King’s College London, has the largest paediatric liver transplantation programme which is closely integrated with the adult programme at UHB. It is a key hub for the NIHR Medicines for Children Research Network. Technology and innovation are at the forefront of the BCH translational plans and a partnership with the McLaren F1 racing team aims to establish remote telemetry of patients across the hospital and the paediatric retrieval ambulance service.
Birmingham already hosts a number of internationally competitive research programmes.

These projects employ in excess of 200 highly skilled staff. Collectively they provide a uniquely valuable resource that has supported the creation and growth of a number of highly successful spin-off SMEs and new research programmes.
Success stories

Collaboration between the two trusts and UoB has historically borne landmark research projects including early phase clinical trials that underpin the ITM’s ability to further develop its portfolio under the leadership of BHP. The UHB/UoB campus is one of the two largest centres for clinical trials in the UK, hosting three clinical trials units. These three trials units form the Birmingham Centre for Clinical Trials.

The Cancer Research UK Clinical Trials Unit (CRCTU) is one of the largest cancer trials units in the UK. It was one of the first NCRI accredited units and is a UKCRC registered trials unit.

The unit has long-standing expertise in a range of cancers, delivering phase I-III trials and hosts both the National Leukaemia and Lymphoma Trials Acceleration Programme that provides support to clinicians in the development of phase I and II trials in haematology and the national Children’s Cancer Trials team.

The early phase trial portfolio incorporates trials from the designated Experimental Cancer Medicine Centre and the Unit supports the trials activity of the NIHR Biomedical Research Unit for Hepatology. In January 2010 Birmingham also became a CRUK Tissue Hub.

The Primary Care Clinical Research and Trials Unit (PC-CRTU) is one of the largest and longest running academic primary care facilities in Europe for clinical trials and longitudinal epidemiology in community population settings which in turn gives access to large and diverse primary care populations through the Primary Care Research Network (PCRN).

The unit has an international reputation for large-scale clinical trials, particularly within the area of cardiovascular disease, with a proven track record of Health Technology Assessments within community settings.

This relationship also uniquely provides a platform for reverse translation where clinical need can drive technological development.

The Birmingham Clinical Trials Unit researches the best treatment in a wide range of medical problems, specialising in large-scale trials in chronic conditions such as Alzheimer’s, Parkinson’s and renal disease.

BCTU has grown rapidly since its inception in 1997, having been awarded funding of over £30 million, and now has 45 staff running some 20 trials.

The campus is also home to the National Institute of Health Research/Wellcome Trust Birmingham Clinical Research Facility (NIHR/WT Birmingham CRF) which comprises an adult facility at UHB and a satellite paediatric facility that opened in 2008.
The strong drive towards development of research capacity, capability and excellence within the three institutions delivers recognised success.

Inflammation Research Facility (IRF)

The IRF is a clinical facility focusing on inflammation, based within QEHB and run under the governance of the NIHR/WT Birmingham CRF. The unit allows a cross-disciplinary approach to inflammation and includes the careful characterisation of cohorts of patients. The facility links directly to UoB research labs and provides unique synergies between laboratory and clinical data within primary and secondary care to clinical research data, alongside a holistic and innovative approach to chronic inflammation.

Birmingham Chronic Disease Resource Centre (CDRC)

The Birmingham CDRC houses clinics in which cohorts of patients with arthritis, kidney, lung and endocrine disease can be studied using shared facilities, while at the same time providing resources for disease specific assessments. There is a cross-disciplinary approach to inflammation with careful characterisation of patient groups to explore how pathology is manifested and differs across different organs and to explore cardiovascular, bone and periodontal co-morbidity.

ECMC (Experimental Cancer Medicine Centre)

Birmingham ECMC aims to improve the feasibility and quality of research in the areas of immunotherapy and gene therapy, translational genetics and biomarkers. This is being conducted in many different types of cancer. The centre has established bio-repositories, developed antibody-based assays and conducted various immunotherapy/gene therapy trials.

Centre for Rare Diseases

Supported by funding from the QEHB Charity, the Centre for Rare Diseases will be situated within the ITM and will be the first comprehensive centre of excellence for rare diseases of its kind in the country. It will support a radical new approach to care that experts hope will dramatically improve treatment and outcomes for people with rare diseases.

Advanced Therapies Facility

This is an expansion of the flagship NIHR/WT Birmingham CRF and is enabling and embedding research in gene and cell-based therapies into clinical research. It is the only facility of its kind in the Midlands and just one of a few across the UK.

Birmingham Centre for Clinical Haematology

The centre oversees one of the most active and academic clinical haematology practices in the world. The centre hosts an internationally-competitive early phase clinical trials portfolio. Its mission is to develop and deliver novel drug and transplant therapies in patients with haematological malignancies.

NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC)

Based at the QEHB, the NIHR SRMRC is a national centre for trauma research, taking discoveries from the military frontline to improve outcomes for all patients in the UK. It brings together pioneering advances in surgery and infection by both military and civilian scientists as well as clinicians to deliver excellence in innovation in a complex area of acute care. Launched in 2011, the centre harnesses expertise from the Ministry of Defence (MoD), University of Birmingham (UoB), and QEHB and has been funded over five years with a total of £15 million investment (£5 million QEHB and UoB; £5 million MoD; £5 million NIHR).
Our success is evidenced through the number of high profile research awards over recent years. These include:

- The highest national award (£12.8m) for the National Institute for Health Research/Wellcome Trust Birmingham Clinical Research Facility (NIHR/WT Birmingham CRF) infrastructure.
- The NIHR Surgical Reconstruction and Microbiology Research Centre.
- No gap continuance awards for the NIHR Liver Birmingham Research Unit (BRU) and Experimental Cancer Medicine Centre (ECMC).
- Arthritis Research UK Early Experimental Arthritis; Cancer Research UK Clinical and Technology Hub status awards.

UHB has also been recognised as a Centre of Excellence for its world-class haematological cancer research by the Leukaemia and Lymphoma Research charity.
Our people

The NHS and academic establishments behind the ITM host a wealth of expertise in some of the most respected leaders in their fields. This strong clinical academic leadership is spearheaded by:

**Professor David Adams**
Birmingham Health Partners Director and Professor of Hepatology and Dean of Medicine at UoB

David’s clinical interests are transplant hepatology and autoimmune liver disease. Laboratory research interests are focused on mechanisms of immune-mediated liver disease. He is currently an associate editor of Liver Transplantation and the American Journal of Physiology and special section editor for the Journal of Hepatology.

**Professor Paul Cockwell**
Chair, BHP Research Strategy Group, Associate Director of Research: Chronic Disease and Personalised Medicine, UHB

Paul is a consultant nephrologist at UHB and an honorary professor at UoB. He is Associate Director of Research at UHB. Paul leads a large clinical research team and is principal investigator on several multicentre clinical studies.

**Professor Eric Jenkinson**
Director of MRC Centre for Immune Regulation, Pro-Vice Chancellor and the Head of the College of Medical and Dental Sciences, and Professor of Experimental Medicine at UoB

Eric is internationally known for his work on the thymus and T-cell development and for the development of novel assays which are widely used for studies in this area.

**Professor Charles Craddock**
Director of the Centre for Clinical Haematology at UHB

Charles is also Professor of Haematology at UoB and leads an active clinical trials programme devoted to the design of novel drug and transplant therapies in acute and chronic myeloid leukaemia.

**Dr Bruce Morland**
Director of Research and Development, BCH

Bruce is a consultant paediatric oncologist, Director of Research and Development and Deputy Medical Director at BCH. His main interests include Phase I/II clinical trials in new anti-cancer therapies and the management of bone and liver tumours.

**Professor Pam Kearns**
Professor of Clinical Paediatric Oncology in the School of Cancer Sciences, UoB and Honorary Consultant, BCH

Pam is Director of the CRUK CTU in the School of Cancer Sciences and is on the Executive Board of the European Society of Paediatric Oncology (SIOP-E); on the Executive Board of the academic consortium ‘Innovative Therapies for Children with Cancer’ and is Vice-Chair of SIOP-E’s European Clinical Research Council for paediatric and adolescent oncology.
Professor Melanie Calvert  
Professor of Outcomes Methodology, UoB  
Melanie has extensive experience in the design and analysis of clinical trials, trials methodology research, economic evaluation and clinical epidemiology. Her primary research interests focus on outcomes research, including the use of composite and patient reported outcomes, notably quality of life. Professor Calvert has over 80 publications, including work in major international journals such as the BMJ, NEJM, Circulation and JAMA.

Professor Lorraine Harper  
Head of Clinical Academic Training, MDS, and Professor of Nephrology, UoB  
Lorraine has published over 70 research papers in scientific journals as well as reviews and book chapters in the fields of inflammation and nephrology. She has received major grants from Kidney Research UK and the Medical Research Council.

Dr Simon Ball  
Consultant Nephrologist, UHB  
Simon qualified in medicine from Oxford University and University College London. He has a wide nephrology practice and is published in various fields. He trained in nephrology and transplantation at St Mary’s Hospital. He is Chairman of Research for British Renal Society.

Dr Graham Lipkin  
Consultant Nephrologist, UHB  
Graham is a Consultant Adult Nephrologist and leads the Centre for Rare Diseases which will be one of the first departments in the ITM. His specialist interests are renal transplantation, pregnancy in women with kidney disease, metabolic renal disease, renal artery stenosis and hypertension.

Dr Tom Clutton-Brock  
Interim Director, Institute of Translational Medicine  
Tom first qualified in medicine from Bristol University in 1980. He has gone on to gain an MRCP and an FRCA. He is a consultant anaesthetist at UHB and carries out research for UoB and is internationally recognised as an expert in medical devices.

Professor Hisham Mehanna  
Chair, Head and Neck Surgery  
Director, Institute of Head and Neck Studies and Education (InHANSE) in the School of Cancer Sciences, UoB  
Hisham is a head and neck and thyroid surgeon with clinical interests in microvascular reconstructive surgery and endoscopic thyroid and parathyroid surgery. He has a keen interest in clinical research, especially in clinical trials evaluating the efficacy and effectiveness of new interventions, therapeutic agents and biomarkers in head and neck and thyroid cancer.
Our history and our future

The ITM will be housed in the historic Queen Elizabeth Hospital (QE), behind its striking 1930s façade. The hospital has a distinguished history and is a local landmark, having served generations of families from Birmingham and beyond.

Its roots were planted in April 1930, when an expanding Birmingham population and the need to combine the scientific advances taking place at UoB with access to clinical services, prompted the revival of earlier plans for a new medical centre.

In 1933 construction began at the site, with the Prince of Wales laying the Foundation Stone on 23 October 1934.

The building was designed by Thomas Arthur Lodge of London architects Lanchester and Lodge, and was constructed to include 740 beds for regular patients with an extra 100 for paying patients.

On 31 December 1938 the Birmingham Hospitals Centre was opened by the Duke of Gloucester and his wife. It consisted of the Vincent Medical Block, the Cadbury Surgical Block and Nuffield House nurses’ home.

The official opening took place on the 1 March 1939. It was attended by King George VI and Queen Elizabeth, who famously delighted the local crowds by giving her name to the hospital unannounced.

In 1995 the QE, along with the old Selly Oak Hospital, became part of the University Hospital NHS Trust.

In September 1999, the Cancer Centre and Patrick Room drop-in support service opened, heralding a new era of more effective investigation and treatment and putting the QE at the heart of a comprehensive, regional service network.

The transfer of services from the QE and Selly Oak hospitals into QEHB was a gradual process carried out in a series of seven phased moves from June 2010 to March 2012.

The merger onto the new site, in close proximity to the UoB Medical School, brought together all major sub-specialties and academics for the first time in the Queen Elizabeth campus’ history.

In July 2012 the Government announced funding towards the construction of the ITM as part of the City Deal for Birmingham. Construction work started in May 2014 and will be completed by July 2015.

In 2015 the QE, along with the old Selly Oak Hospital, became part of the University Hospital NHS Trust.

In September 1999, the Cancer Centre and Patrick Room drop-in support service opened, heralding a new era of more effective investigation and treatment and putting the QE at the heart of a comprehensive, regional service network.
It is recognised that SMEs and major pharmaceutical companies require simple and effective access to both the NHS and academia. The ITM will provide this single point of entry for the commercial, pharmaceutical and technology sectors, from inception to proof-of-concept testing.

The commercial hub offers signposting and an introduction to clinical and academic staff; facilitates innovation through concept development to address “real-world” problems, and supports intellectual property and commercialisation identification and processing.

Unlock growth
Working with community and industry partners, the ITM will respond to national unmet need, unlock growth potential in the NHS and develop a portal to create a resource for SMEs and international pharmaceutical companies.

Situated close to the ITM is the BioHub Birmingham, a new facility designed to provide entrepreneurs and innovative start-ups with access to affordable, fully managed, shared laboratory facilities and a base in which to locate their business.

Locating pharmaceutical firms with clinicians and academics will provide opportunities for export-rich growth and employment.

The ITM will provide serviced office space for SMEs; meeting and networking facilities; access to support, advice and finance potential through links with Birmingham Finance, Birmingham City Council, the Chamber of Commerce and Academic Health Science Network, all supported by conferencing facilities, video conferencing and seminar rooms.

Job creation
The ITM will offer opportunities to develop a post-graduate training programme in translational medicine alongside joint NHS/private sector scientific and professional development courses.

The ITM will create in excess of 2,000 high-value jobs long-term in clinical trials, diagnostics and adjunctive Life Science industries, including those from spin-outs, expansions of existing SMEs and inward investment.

The ITM concept and delivery will be a national demonstrator of ‘how to do it’ – lending itself to replication in other sectors across the UK.
FRONT ‘C’ PLAN OF NORTH BLOCK COMMERCIAL/COMMUNITY GROUND TO FIFTH (EXCL. THIRD) FLOOR

CLINICAL RESEARCH GROUND FLOOR WEST BLOCK

MAIN ENTRANCE
PUBLIC ENTRANCE

NORTH BLOCK
Ground floor

WEST BLOCK
Ground floor
Contacts

Institute of Translational Medicine
Telephone: 0121 371 4820
Email: itm@uhb.nhs.uk
Website: www.birminghamhealthpartners.co.uk/institute-of-translational-medicine.htm